Sarah Gilbert, professor at Oxford University, who led the development of the AZD1222 coronavirus vaccine, evaluated the combination of the British drug with Sputnik V. It is reported by RBC with reference to the BBC.
According to her, AZD1222 may be more effective in combination with other drugs, including the Russian vaccine. She added that this will be explored in a relatively “small study”.
Earlier, the British pharmaceutical company AstraZeneca announced the beginning of clinical trials of a combination of its AZD1222 vaccine and the Russian drug Sputnik V. The AZD1222 vaccine was developed on the basis of an adenoviral vector – a genetically modified adenovirus. Adenoviral vectors with embedded coronavirus S-protein also form the basis of the Sputnik V two-component vaccine.
